Exploring the therapeutic efficacy of glioma vaccines based on allo- and syngeneic antigens and distinct immunological costimulation activators by Stathopoulos, A. et al.
Journal of Clinical & Cellular Immunology – Open Access using online manuscript submission, review and tracking systems of Editorial Manager® for 
quality and quick review processing. Submit your manuscript at http://www.editorialmanager.com/clinicalgroup
OMICS Publishing Group
5716 Corsa Ave., Suite 110, Westlake, Los Angeles, CA 91362-7354, USA, Phone: +1- 650-268-9744, Fax: +1-650-618-1414, Toll free: +1-800-216-6499
http://www.omicsonline.org/jccihome.php
Journal of Clinical & Cellular Immunology
ISSN: 2155-9899
C J. Malemud
Case Western 
Reserve University
USA
C E. Egwuagu
Laboratory of 
Immunology, USA
Fernando Villalta
Meharry Medical 
College, USA
M von Herrath
University of 
California, USA
Kalipada Pahan
Rush University 
Medical Center, USA
Y Abu Kwaik
University of Louisville 
USA
W. Martin Kast
University of Southern 
California, USA
Haval Shirwan
University of Louis-
ville, USA
Pere Santamaria
University of Calgary 
Health Sciences 
Centre, Canada
Daniel Kaufman 
Molecular & Medical 
Pharmacology, USA
Noah Isakov 
Ben Gurion University 
of the Negev
Israel 
Antonino Carbone
Coordinator National 
Telepathology Network 
Italy
Robert A Murgita 
McGill University
Canada
Achim Temme
Technical University 
Dresden, Germany
Satoshi Kamei
Nihon University
Japan
Mark S. Kindy
Medical University of 
South Carolina, USA
Immunology referring and relating the interactions among cells 
and molecules of the immune system, and how such interactions 
bestow to the recognition and elimination of pathogens. Journal of 
Clinical & Cellular Immunology publishes original, trusted leading 
edge scientifi c and highly peer reviewed investigations pertained 
with the immunological activities of cells in experimental or clinical 
situations. This journal provides an international forum for the 
publication of original research on all aspects of clinical immunology 
and cellular immunology. 
Lisbeth Berrueta
University of Los 
Andes, Venezuela
Emanuela Signori
University Campus 
Bio-Medico of Rome
Italy
Hong Wei Chu
University of Colorado 
Denver, USA
Bing  Su
Immunobiology Yale 
University, USA
Anshu Agrawal
University of Califor-
nia, USA
Jin Wang
Baylor College of 
Medicine, USA
Elliot Rosenstein
Mt. Sinai School of 
Medicine, USA
Karsten Gronert
University of Califor-
nia, USA
V K. Tsiagbe
University of Medicine 
and Dentistry of New 
Jersey, USA
Horea Rus
 University of Mary-
land, USA
Amr H Sawalha
University of 
Oklahoma, USA
C C. Caldwell
University of Cincinnati 
College of Medicine
USA
Kota. V Ramana
University of Texas  
USA
S Markovic-Plese 
University of North 
Carolina, USA
David A. Scott
University of Louis-
ville, USA
J Bassaganya-Riera
Virginia Bioinformatics 
Institute, USA
V Rivera Amill
Ponce School of Med-
icine, Puerto Rico
A Rahman Asif
George-August-Uni-
versity, Germany
John C. Cambier
University of Colorado
USA
R R Gonzalez-Perez
Morehouse School of 
Medicine, USA
Pooja Jain
Drexel University
USA
Azizul Haque
Medical University of 
South Carolina, USA
Mark Barton Frank
Arthritis and Clinical 
Immunology, USA
Jan Storek
University of Calgary 
Staff Physician 
Canada
Research Article Open Access
Stathopoulos et al., J Clin Cell Immunol 2012, S5
http://dx.doi.org/10.4172/2155-9899.S5-004
Research Article Open Access
Clinical & Cellular
Immunology
J Clin Cell Immunol                                                                                                                                 ISSN:2155-9899 JCCI, an open access journal Cancer Immunology
*Corresponding authors: Dr. Virgil E.J.C. Schijns, Cell Biology & Immunology 
Group, Wageningen University, PO Box 338, 6700 AH Wageningen, The 
Netherlands, E-mail: Virgil.schijns@wur.nl
Dr. Apostolos Stathopoulos, Department of Neurosurgery, Arlon Hospital, Arlon, 
Belgium, E-mail: tstath@hotmail.com
Received December 16, 2011; Accepted March 06, 2012; Published March 09, 
2012
Citation: Stathopoulos A, Pretto C, Devillers L, Pierre D, Hofman FM, et al. 
(2012) Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and 
Syngeneic Antigens and Distinct Immunological Costimulation Activators. J Clin 
Cell Immunol S5:004. doi:10.4172/2155-9899.S5-004
Copyright: © 2012 Stathopoulos A, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Abstract
The efficacy of a various immunotherapeutic immunisation strategies for malignant glioma brain cancer was 
evaluated in the syngeneic CNS-1 Lewis rat glioma model. A prototype glioma cancer vaccine, which was composed 
of multivalent antigens derived from allogeneic and syngeneic cells and lysates, formed the prototype preparation of 
antigens. These antigens reflect the autologous antigens derived from the patient’s surgically removed tumor tissue, 
as well as allogeneic antigens form glioma tumor tissue surgically removed from donor patients. This antigen mixture 
provides a broad spectrum of tumor associated antigens (TAA) and helps to prevent escape of tumor immune 
surveillance when given as a vaccine. This antigen preparation was administered in a therapeutic setting with distinct 
single or multiple co-stimulation-favouring immunostimulants and evaluated for inhibition of tumor growth. Our 
prototype vaccine was able to arrest progression of tumor growth when co-delivered in a specific regimen together 
with the costimulating multi-TLR agonist, Bacille Calmette Guerin (BCG) and interleukin-2, or with the Toll-Like 
receptor (TLR) 7/8 activator resiquimod. 
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Introduction
Glioblastoma multiforme (GBM) is an invasive malignant tumor 
of the central nervous system. Conventional therapy options include 
surgery, radiation, and chemotherapy, but with them the prognosis 
for GBM patients is limited to a mean survival time of only 14.6 
months [1]. Immunotherapy is emerging as a novel complementary 
treatment option for a variety of malignancies including GBM. The use 
of successful passive immunotherapies based on the administration of 
immune elements, such as antibodies has proven very successful against 
various types of cancer. Well-known examples include antibodies 
that target tumor expressing receptors for epidermal growth factor 
(EGF), called Herceptin, those that target HER-2 [2], and those that 
are directed against angiogenic, tumor blood vessel growth-promoting 
vascular endothelial growth factor (VEGF), known as Avastin [3]. 
Recently, the antibody directed against an immune response inhibitory 
molecule, called cytotoxic T lymphocyte associated protein 4 (CTLA4), 
known as Yervoy®, has shown promising clinical efficacy in melanoma 
patients [4]. 
Apart from these passive antibody-based therapies, a range of 
active immunotherapies are in late stage development and are close 
to reaching approval as standard of care. These clinical studies clearly 
demonstrate that the immune system is able to discriminate cancer 
cells from normal cells following recognition of tumor associated 
antigens (TAA). Indeed a recent approval for a prostate cancer vaccine 
named Provenge®, was obtained from the FDA in April 2010, for the 
treatment of asymptomatic or minimally symptomatic metastatic, 
castrate-resistant (hormone-refractory) prostate cancer [5]. This recent 
approval has rejuvenated interest in the field as a whole. 
In the present study we demonstrate a prototype brain cancer 
vaccine against gliomas which is composed of multivalent antigens 
derived from allogeneic and syngeneic cells and lysates. Our prototype 
is reflected in a clinical situation by autologous antigens derived from 
the patient’s surgically removed tumor tissue. In addition, glioma tumor 
tissue surgically removed from donor patients provides a second source 
of allogeneic antigens that can be isolated and subsequently stored for 
later use. This material provides a new source of TAA that may display 
HLA-restriction that may overlap with that on the patient’s glioma. 
They may serve to enhance the overall immune response. If processed 
under Good Manufacturing Conditions, it may provide an “off-the 
shelf” application. Relevant unique or shared TAAs overexpressed by 
tumor cells are present among thousands of irrelevant immunotolerant 
non-tumor associated antigens. The broad range of TAAs is preferred 
over vaccines with a mono- or oligo-valent antigenic content. These 
vaccines will prevent escape of tumor cells due to antigenic loss, or 
active MHC downregulation. In addition, a tumor antigen mixture 
also circumvents the use of monovalent synthetic peptides, which are 
restricted for use in patients with defined HLA types. By including 
TAAs of allogeneic origin, we additionally trigger allogeneic immune 
reactions. The haplotypes of CNS-1 and RG2 are fairly close, i.e., RT1l 
vs RT1lvl , yet provide a mismatch that may be considered abberant self, 
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and also induce an alloresponse. This may provide better protection 
due to the “non-self” immune recognition of these antigens. 
Although allogeneic tumor antigens may provoke immune 
responses to non-self antigens in classical allogeneic immune rejections, 
glioma tumors, once established, are known to actively suppress 
the host’s immune system, by well characterized mechanisms [6], 
which often leads to subsequent evasion of immune surveillance. We 
therefore decided to test various signaling and costimulation-favouring 
immunostimulants in combination with our prototype vaccine antigen 
formulation for anti-tumor activity in an aggressive rat glioma brain 
tumor model, CNS-1, that is syngeneic in Lewis rats. 
Here we demonstrate that our prototype vaccine is able to arrest 
progression of tumor growth when co-delivered in a specific regimen 
with the costimulatory-enhancing multi-TLR agonist, Bacille Calmette 
Guerin (BCG) adjuvant with interleukin-2, or with the TLR 7/8 
activator resiquimod. 
Materials and Methods
Tumor model 
Glioma cells: Both CNS-1 tumor cells and RG2 (ATCC, CRL-2433) 
rat glioma cells were cultured in Dulbecco’s modified Eagle (DMEM) 
medium containing 10% bovine fetal serum (FBS), 5% antibiotics 
Penicillin, Streptomycin, and amphotericin B (Hyclone) in 175-mm2 
flasks. The CNS-1 haplotype is RT1l and RG2 is RT1lvl.
Animals: Rat CNS-1 cells (2 × 105 cells/200 ul) were implanted 
subcutaneously (SC) using a 21 gauge needle into the right flank of 8-12 
week-old (300 gram body weight) male Lewis rats. For each treatment 
group and control, 4-8 rats/group were used. All animal studies were 
approved by an independent ethical committee.
Monitoring tumor growth
The sizes of the CNS-1 tumor volumes were measured using a 
caliper three times per week on Mondays, Wednesdays and Fridays to 
monitor the effects of each treatment group. 
Completion of experiment
Tumor implanted rats were sacrificed if they showed signs of 
discomfort, as defined by the ethical committee. For example if they 
appeared moribund due to weight loss, lethargy, ruffled fur, or when 
tumors showed ulceration. A mixture of Rompun and ketamine was 
used for anesthesia, followed by a dose of sodium pentobarbital for 
euthansia. 
Vaccine
The vaccine antigen preparation was composed of a mixture of 
haptenized CNS-1 cells and RG2 cells (1 × 10e6 CNS-1 syngeneic and 
1 × 10e6 RG2 allogeneic glioma cells), together with lysates produced 
from 3 × 10e6 CNS-1 syngeneic cells and 3 × 10e6 allogeneic RG2 
glioma cells. The haptinization method has been described before [7].
This vaccine preparation was kept as a constant factor and given 
in combination with various other anti-tumor or immunostimulatory 
agents as specifed in Figures 1A & 2A. The TLR7/8 agonist resiquimod 
was co-administered 3 times a week on Mondays, Wednesdays and 
Fridays.
Chemicals and Reagents 
Immunomodulators and potentiators
Rats were subcutaneously (SC) injected in the flank, contralateral 
to the tumor-implanted side, with resiquimod (R848) (Invitrogen, 
TLRL-R848), a Toll-like receptor 7/8 agonist, at a dose of 100 µg/
kg, corresponding to 30 µg/dose, three times per week on Mondays, 
Wednesdays and Fridays.
In a parallel arm of the experiment we evaluated the effect of 
cyclophosphamide (CY) administration, in diverse regimens and 
dosing as specified, on CNS-1 glioma development. Cyclophosphamide 
(CalBiochem, 239785) was given at 30 mg/kg 3 times per week, or at 
100 mg/kg once every week (See also Figure 1A and 2A). 
We also tested the vaccine antigen preparations combined with 
Bacilles Calmette-Guérin, interleukin-2 (IL-2), or a B7.1 fusion protein.
The Bacilles Calmette-Guérin (BCG), substrain Connaught, 
(Immunocyst®, Sanofi Pasteur) is an agonist of TLRs 2, -4 and -9, was 
used at 2 × 10e5 CFU per dose.
Interleukin-2 (IL-2) was injected daily at a dose of 75,000 IU/day 
from Monday to Friday starting on the day of vaccine injection. 
A B7.1 fusion protein consisting of the extracellular domains of 
human B7.1 and the Fc portion of human IgG1, called B7.1-Fc, was 
produced as described [8]. This protein induced complete regression 
of Colon 26 tumors in a mouse model and slowed tumor growth 
dramatically in mice with established poorly immunogenic RENCA 
and Madison109 tumors [8]. The B7.1-Fc protein was diluted in sterile 
PBS at 250 µg/200µl concentration.
For statistical analysis, we used ANOVA nonparametric testing 
followed by student’s t tests to compare groups. P values of < 0.05 (*), 
p < 0.01 (**), p < 0.001 (***) were considered statistically significant.
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Figure 1: A vaccine was prepared from allogeneic and syngeneic antigens 
and administered in a fractionated regimen together with BCG and IL-2 
to determine the effects on CNS-1 glioma growth. A) Treatment schedule 
representing one cycle of the various immunotherapeutic injections. B) Average 
values of tumor growth as a function of time post-implantation for the different 
treatment groups.
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Results
Efficacy of a BCG-containing vaccine administered at day 17 
after implantation 
CNS-1 tumor cells (2 × 105 cells / 200 µl) were implanted in syngeneic 
male Lewis rats and after 17 days were either left untreated (control 
group; n = 4) or administered with a therapeutic immunomodulatory 
regime or some of its components, as specified in the treatment 
schedule of Figure 1A.
The vaccine antigen preparation consisted of a mixture of 
haptenized 10e6 syngeneic and 10e6 allogenic RG2 glioma cells 
together with lysates produced from 3 × 10e6 synegeic CNS-1 cells 
and 3 × 10e6 allogenic RG2 gliomacells (n = 4). When monitoring 
tumor growth over time with a caliper, we observed no significant 
difference in tumor volumes between the control group (G1) and the 
rats receiving cyclophosphamide (CY) only at a dose of 100 mg/kg (G2) 
(Figure 1). From other experiments we had learned that the vaccine 
antigen preparation showed no anti-tumor efficacy by itself under 
the conditions described (for illustration see also figure 3, the antigen 
only group indicated by closed circles). By contrast, when this vaccine 
antigen preparation was administered together with the multiple 
TLR agonist BCG plus IL-2, an inhibition of tumor growth was noted 
(G6). Similarly, the same treatment schedule supplemented with CY 
(30 mg/kg on day 19, and 80 mg/kg on day 31) also inhibited tumor 
growth (G4). Remarkably, also five daily injections of B7.1-FC fusion 
protein alone (Monday to Friday, starting day 17 post implantation), 
showed some inhibition of tumor growth (G3), though not statistically 
significant relative to control groups. However, when combining the 
beneficial vaccine preparation plus CY (30 mg/kg) treatment with an 
additional regimen of B7.1-Fc antibody injections no inhibition of 
tumor growth was noted (G5). 
A BCG-containing vaccine shows better efficacy amongst the 
diverse vaccine prototypes tested 
In a subsequent experiment, CNS-1 tumor cells (2 X 105 cells / 200 
µl) were implanted in 8-12 week-old syngeneic male Lewis rats and 
were either left untreated (control group; n = 4) or administered with 
a therapeutic immunomodulatory treatment regimen or some of its 
components, as specified in the treatment schedule depicted in Figure 
2A. Instead of waiting until day 17 post tumor implantation, we now 
started at day 10 after tumor inoculation.
As before, the vaccine antigen preparation consisted of a mixture 
of haptenized syngeneic CNS-1 and allogeneic RG2 glioma cells 
(10e6 each) with lysates produced from syngeneic CNS-1 cells and 
allogeneic RG2 glioma cells (3 × 10e6 each) (n = 4). When monitoring 
tumor growth over time with a caliper, we observed no significant 
difference in tumor volumes between the untreated control group (G1) 
and the rats receiving low dose cyclophosphamide (CY, 30 µg/dose) 
in week two (G4), B7.1-Fc fusion protein only (G3), B7.1-Fc protein 
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Figure 2: A vaccine was prepared from allogeneic and syngeneic cells 
administered in a fractionated regimen together with BCG and IL-2. A) 
Treatment schedule representing the cycle of the various immunotherapeutic 
injections. AC, allogenic cells, SC, syngeneic cells, AL, allogeneic lysate, SL, 
syngeneic lysate, Ly, is lysate only. B) Average values of tumor growth as a 
function of time post-implantation for the different treatment groups.
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Figure 3: A vaccine was prepared from the standardized allogeneic and 
syngeneic cells administered  with or without the TLR7/8 agonist, resiquimod, 
injected 3 times a week on Mondays, Wednesdays and Fridays. Average values 
of tumor growth as a function of time post-implantation for the different treatment 
groups.
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Figure 4: Individual tumor growth curves as a function of time post-implantation.
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plus CY (G2) or vaccine plus CY only (G5) (Figure 2A). By contrast, 
when this vaccine antigen preparation was administered together 
with the multiple TLR agonist BCG plus IL-2 and CY (100 µg/dose), 
a significant inhibition (p < 0.05) of tumor growth was noted (G6). 
This vaccine preparation was administered in a fractionated schedule 
starting with allogeneiic cells on the first day, followed by syngeneic 
cells the second day, and allogeneic and syngeneic lystates on the third 
and fourth days, respectively (G6). Remarkably, also ex vivo tumor 
tissue isolated from a syngeneic established CNS-1 tumor plus CY (G7) 
showed some inhibition of tumor growth (although not statistically 
significant) relative to control groups (Figure 2B).
Therapeutic treatment with a vaccine containing 
immunostimulatory TLR7/8 agonist shows marked inhibition 
of glioma tumor growth
In view of the beneficial effect of vaccination in the context of the 
multi-TLR agonist BGC, we decided to evaluate the effect of a TLR7/8 
agonist in our CNS-1 tumor model. CNS-1 tumor cells (2 X 105 cells 
/200 µl) were implanted in 8-12 week-old syngeneic male Lewis rats 
and either left untreated (control (CTRL) group; n = 8) or treated at 
day 10 after implantation with a vaccine antigen preparation consisting 
of a mixture of haptenized syngeneic CNS-1 and allogeneic RG2 
glioma cells (10e6 each) with lysates produced from syngeneic CNS-1 
and allogeneic RG2 glioma cells (3 × 10e6 each) (n = 8), given alone or 
combined with the TLR7/8 agonist, resiquimod (R848). This vaccine 
preparation was given 3 times a week on Mondays, Wednesdays and 
Fridays. When monitoring tumor growth over time with a caliper, we 
observed no significant difference in tumor growth between control 
and vaccine antigen only treated rats (Figure 3). By contrast, when this 
antigen preparation was administered together with a TLR7/8 agonist 
(30 µg/dose) significant inhibition (p, 0.001, ***) of tumor growth, 
with complete tumor regression was noted (Figure 3). Remarkably, 
administration of TLR7/8 agonist alone in the same regimen also 
inhibited tumor (p, 0.001, ***) (Figure 3).
Inhibition of tumor progression with large established glioma 
tumors by a vaccine containing the TLR7/8 immunostimulant 
As mentioned above, Lewis rats treated with a vaccine without 
immunostimulatory TLR7/8 agonist showed little inhibition of tumor 
growth relative to untreated control rats, while the TLR7/8 containing 
vaccine strongly suppressed tumor growth when given 3 times per 
week starting at day 10 after implantation. We therefore decided 
to examine the effect of therapeutic vaccination of animals which 
showed no inhibition of tumor growth at day 34 after implantation. 
We administered the TLR7/8 containing vaccine to animals with large 
(12-14,000 mm3) tumors, starting at 38 days after tumor implantation. 
The TLR7/8 agonist-containing vaccine was injected 3 times a week 
on Mondays, Wednesdays and Fridays, in both untreated control rats 
(n=4) and rats immunized with idential antigen only (n=4). We noted 
in both groups a slower rate of growth of gliomas with large tumor 
volumes, but the TLR7/8 containing vaccine was best able to evoke a 
significant (p < 0.001, ***), arrest of tumor volume growth in the rats 
that were treated before with the antigen only vaccine preparation, 
relative to rats which were untreated (Figure 4). As well, no signs 
of vaccination-induced adverse effects or toxicity were observed, 
confirming data from another study that immunotherapy is well 
tolerated with limited toxicity [9]. These untoward effects point to the 
relative safety and tolerability of vaccines.
Discussion
In the present study we show that a prototype vaccine, consisting 
of a mixture of allogeneic and syngeneic glioma cells and their lysates, 
administered together with either a multiple TLR2, -4 and -9 agonist 
BCG [9], or the TLR7/8 agonist resiquimod, is able to inhibit CNS-
1 glioma brain tumor growth in syngeneic Lewis rats. For early stage 
tumors, a complete regression of tumor growth volume was noted, 
while for large established 38-day old tumors (14,000 mm3 volume), 
inhibition of tumor growth was noted for the TLR7/8 containing 
vaccine. These data confirm the well-know phenomenon that large 
glioma tumors are more difficult to control relative to smaller tumors. 
Nevertheless, if the latter is most relevant to the large tumor burden 
that may be present in individuals with gliomas in unresectable sites 
(e.g. parietal or tempero-parietal tumors), instituting vaccination with 
TLR agonists may be valuable in providing additional quality survival 
time.
During glioma tumor development a proportional increase in local 
and systemic immunosuppression has been documented [6,9,11,12]. 
Gliomas are known to contain T regulatory cells, which normally act as 
suppressor cells, regulating homeostatis and preventing autoimmune 
reactions. However, regulatory T cells also inhibit T effector 
functions, activated naturally by vaccination [13,14], and thereby 
facilitating tumor immune evasion and subsequent tumor progression. 
At the molecular level this is associated with an increase in production 
of immune inhibitory cytokines including transforming growth fcator 
(TGF)-beta, and/or interleukin-10 [15]. In general, immunosuppression 
can be counteracted by either strong stimulation of proinflammatory 
immune pathways, by blocking immune inhibitory elements triggered 
by the tumor itself, or by a combined “push-pull” approach [16]. 
We therefore evaluated well-known costimulation-enhancing 
immunostimulants, such as TLR-agonists [17], and inhibitors of 
immune system signals, such as what the B7.1 and cyclophosphamide 
immunomodulators provide. They were administered in conjunction 
with our standard vaccine antigen preparation. 
We noted beneficial antitumor activity with daily injection of the 
B7.1Fc fusion protein starting at day 17 after tumor implantation as 
a monotherapy. This soluble costimulator protein was fused to the 
Fc portion of the antibody. It has been developed and tested for the 
immunotherapy of solid tumors in mouse tumor models [8]. This B7.1-
Fc protein was found to be capable of activating T cells in vitro and in 
vivo [8]. B7.1 is able to engage with two known receptors. CD28, which 
triggers a stimulatory signal to activate naive T cells after binding by 
B7.1 (4), and its counterreceptor, CTLA-4, which triggers a negative 
signal to stop T-cell activation. Since B7.1 has high affinity to CTLA-4, 
soluble B7.1-Fc may block CTLA-4 signaling instead of cross-linking 
CTLA-4, thereby sustaining the activation of tumor-specific T cells 
[18,19]. Crosslinking of T cell activating CD28 may be less important 
than blocking the inhibitory CTLA-4, since activated T cells recognizing 
tumor antigens requires less costimulation [20]. When B7.1 antibody 
was combined with other immune system activating treatments, we 
observed no synergistic activities, which illustrates that the timing and 
choice of modalities during combined immunotherapy is criticical for 
a beneficial antitumor effect.
Also, cyclophosphamide, when dosed carefully, has been 
demonstrated to facilitate immunotherapy of established tumors 
through the elimination/inactivation of suppressor T cells [21-
23]. In our investigations, a protocol of cyclophosphamide (CY) 
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only, administered at a dose of 100 mg/kg given on day 19 post 
transplantation did not affect tumor growth (Figure 1), while three 
lower doses of 30 mg/kg each starting on day 17 given within a week 
period, did not show a beneficial anti-tumor activity (Figure 2). By 
contrast, CY treatment alone may even exacerbate tumor growth, 
relative to the untreated control group, which may likely result from 
suppression of endogenous anti-tumor immune reactions in parallel to 
inadeqaute direct tumor growth inhibition, resulting in a net increase 
in tumor growth volume. Nevertheless, when combined with other 
immune adjuvants or vaccines, beneficial effects were noted despite co-
administration of CY. 
The best efficacy was noted in treatment schedules containing the 
vaccine antigen preparation plus BCG and IL-2. Bacillus Calmette-
Guérin (BCG) is a mycobacterium which contains various agonists of 
Toll-like receptor 2 (TLR2) and TLR4 in its cell wall skeleton (CWS), 
and also BCG DNA which acts as a TLR9 agonist [10,24]. Intravesical 
immunotherapy with BCG, as monotherapy, causes significant 
reductions in cancer tumor progression and is currently the standard 
treatment for superficial bladder cancer [25]. However, the exact mode 
of action of successful BCG therapy remains elusive, although massive 
cytokine expression and influx of innate immune cells have been 
documented, which may be involved in tumor elimination. 
Apart from BCG, we also examined the effect of the TLR7/8 agonist 
resiquimod as an adjuvant in a separate animal study. TLR7/8 agonists 
exert pleiotropic effects on various immune cells which leads to 
stimulation of proinflammatory cytokine and chemokine production, 
as well as up-regulation of costimulatory molecules on antigen 
presenting cells [26]. The TLR7/8 agonist resiquimod has been shown 
to act as a vaccine adjuvant in investigational vaccine models [25,27], 
and to generate clinical-grade mature DCs [28].
In our CNS-1 model, the TLR7/8 agonist resiquimod showed 
superior antitumor effects against early tumor growth and remarkably, 
administration of TLR7/8 agonist alone inhibited tumor growth. The 
exact mode of action for the observed resiquimod-mediated anti-tumor 
immunity needs to be defined in detailed follow-up studies. Most likely 
the observed resiquimod-based immunotherapy, even in absence of 
additional tumor antigens, is able to activate a spontaneous, natural, 
innate anti-tumor immune response, that under normal circumstances 
is unable to control tumor growth. Hence, such dedicated follow-
up studies need to address to involvement of anti-tumor killer 
macrophages or NK cells, or IFNs for the resiquimod-induced glioma 
growth regression. In addition, the TLR7/8 vaccine preparation evoked 
an arrest of tumor volume growth in rats carrying large tumors that 
were treated before with the antigen only vaccine preparation. 
Although the presented results are promising the should always 
be interpretaed with caution. Subcutaneous tumors may be exposed 
to markedly distinct immune conditions than in the brain, and so the 
physiologic as well as clinical relevance has to be validated in further 
studies. 
Our vaccine preparation contains multiple tumor associated 
antigens (TAA) prepared from syngeneic and allogeneic cells. 
Although the precise identity of antigens is unknown we chose this 
antigen preparation for our vaccination strategy, rather than one or a 
few molecular targets, in order to target multiple TAAs simultaneously. 
This approach minimizes the chances for classical tumor-escape of 
immune control, as a result of selective growth of antigen-loss variants. 
With this approach we guaranteed that multiple relevant TAAs gain 
enhanced exposure to the immune system, while the self-antigens in 
this mixture are neglected as a result of immunological tolerance. By 
including cell associated antigens, we increased the chance of cross-
presentation by MHC class I molecules for priming of cytolytic CD8+ 
T cells. By including TAAs of allogeneic origin, we additionally trigger 
allogeneic immune reactions. The haplotypes of CNS-1 and RG2 are 
fairly close, i.e., RT1l vs RT1lvl thus providing a mismatch that may 
be considered abberant self, and also induce a vigorous alloresponse. 
Allogeneic (major histocompatibility complex MHC-mismatched) 
tumor cells have shown better protection in a number of models likely 
due to the “non-self” immune recognition of these antigens [29-31].
Immunotherapy against TAA theoretically carries the risk of 
autoimmune reactions. Autoimmunity is possible, especially in view 
of our manipulations aimed at blocking immune response inhibitors 
coupled with the use of immunostimulating adjuvants. In the present 
studies, however, we have not observed any adverse reactions using our 
animal well-being scoring system. These observations are in line with 
well-documented observations, that therapeutic tumor vaccination is, 
in general, well-tolerized with minimal or no adverse events.
In conclusion, we noted beneficial antitumor activity of daily 
injection of the B7.1-Fc fusion protein as monotherapy, and with 
vaccine preparations that were administered with BCG and IL-2 only, 
or with the TLR7/8 agonist resiquimod. Altogether these data illustrate 
the importance of a beneficial immunomodulatory protocol. Different 
immunomodulators may result in distinct antitumor efficacy. Hence, 
we conclude from our data that only specific combinations of the right 
antigenic mixtures in conjunction with a suitable immunopotentiator 
is able to arrest aggressive glioma tumor growth in this experimental 
tumor model. Our data highlight the need for continued, more 
extensive exploration into such combinations.
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